These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 36605401)
21. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients. Hau RK; Wright SH; Cherrington NJ Clin Transl Sci; 2022 Jul; 15(7):1599-1605. PubMed ID: 35505633 [TBL] [Abstract][Full Text] [Related]
22. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong. Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790 [TBL] [Abstract][Full Text] [Related]
23. Molnupiravir and Its Antiviral Activity Against COVID-19. Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J Front Immunol; 2022; 13():855496. PubMed ID: 35444647 [TBL] [Abstract][Full Text] [Related]
24. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models. Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK Nat Commun; 2023 Aug; 14(1):4731. PubMed ID: 37550333 [TBL] [Abstract][Full Text] [Related]
25. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795 [TBL] [Abstract][Full Text] [Related]
27. Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses. Ardanuy J; Johnson R; Dillen C; Taylor L; Hammond H; Weston S; Frieman M mBio; 2023 Oct; 14(5):e0158723. PubMed ID: 37581442 [TBL] [Abstract][Full Text] [Related]
28. Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection. Tan YL; Tan KSW; Chu JJH; Chow VT Front Cell Infect Microbiol; 2021; 11():700502. PubMed ID: 34395311 [TBL] [Abstract][Full Text] [Related]
29. A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents. Do TND; Donckers K; Vangeel L; Chatterjee AK; Gallay PA; Bobardt MD; Bilello JP; Cihlar T; De Jonghe S; Neyts J; Jochmans D Antiviral Res; 2021 Aug; 192():105122. PubMed ID: 34186107 [TBL] [Abstract][Full Text] [Related]
30. Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques. Rosenke K; Lewis MC; Feldmann F; Bohrnsen E; Schwarz B; Okumura A; Bohler WF; Callison J; Shaia C; Bosio CM; Lovaglio J; Saturday G; Jarvis MA; Feldmann H bioRxiv; 2022 Sep; ():. PubMed ID: 36263071 [TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19. Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK bioRxiv; 2022 Feb; ():. PubMed ID: 35169793 [TBL] [Abstract][Full Text] [Related]
36. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19. Atmar RL; Finch N Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759 [TBL] [Abstract][Full Text] [Related]
37. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature. Marangoni D; Antonello RM; Coppi M; Palazzo M; Nassi L; Streva N; Povolo L; Malentacchi F; Zammarchi L; Rossolini GM; Vannucchi AM; Bartoloni A; Spinicci M Int J Infect Dis; 2023 Aug; 133():53-56. PubMed ID: 37150351 [TBL] [Abstract][Full Text] [Related]
38. Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model. Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35579953 [TBL] [Abstract][Full Text] [Related]
39. Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression. Franco EJ; Drusano GL; Hanrahan KC; Warfield KL; Brown AN Viruses; 2023 May; 15(5):. PubMed ID: 37243261 [TBL] [Abstract][Full Text] [Related]
40. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]